Combination Immune Checkpoint Inhibition: Is First Line Best?

Grant A McArthur^{1

2}

Affiliations

¹ Cancer Research Division and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

Editorial

Grant A McArthur. J Clin Oncol. 2023.

. 2023 May 20;41(15):2691-2694.

doi: 10.1200/JCO.23.00061. Epub 2023 Feb 28.

Grant A McArthur^{1

2}

¹ Cancer Research Division and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

No abstract available

Comment on

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Ascierto PA, et al. J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13. J Clin Oncol. 2023. PMID: 36780608 Free PMC article.